lamdis

How to appeal a Mounjaro denial

Reviewed · 25 sources

The short answer

Mounjaro is approved only for people with type 2 diabetes, and plans generally cover it for that use. If you have diabetes and were denied, look first at missing records or the plan's drug list; an appeal or a formulary exception addresses both. If Mounjaro was prescribed for weight loss without diabetes, Medicare cannot cover it and private plans may list that use as not covered; the drug approved for weight management is Zepbound.

What Mounjaro is approved for

Mounjaro (tirzepatide) was first approved on May 13, 2022 to improve blood sugar control in adults with type 2 diabetes. Two changes followed:

Every use on the current label is for people with type 2 diabetes. The same active ingredient is sold as Zepbound, which the FDA approved for weight management.

If you have type 2 diabetes and were denied

KFF reports that health plans generally cover these drugs when prescribed for diabetes. Check the denial letter for one of these three problems.

Missing proof of diabetes. One insurer's employer-plan policy, effective June 2026, approves Mounjaro with a documented type 2 diabetes diagnosis. It says documentation can include chart notes, lab tests, claims records and prescription receipts. Ask your doctor's office to send the diagnosis, recent lab results such as your A1c, and your list of diabetes medicines.

Step therapy. Some plans want you to try another drug first. In a 2024 Peterson-KFF review, fewer than 1 in 4 Marketplace plans used step therapy for each GLP-1 drug studied. If you have already tried the required drug, send the dates and results. See step therapy denials.

Not on the drug list. The plan may prefer a different GLP-1. A formulary exception is the route.

File the internal appeal within 180 days. Denials that turn on medical judgment can go to external review if the plan says no again.

If Mounjaro was prescribed for weight loss

Using Mounjaro for weight loss without diabetes is off-label. One insurer's national policy lists weight loss under conditions not covered, noting that the diabetes GLP-1s are not FDA-approved for weight loss. Medicare Part D excludes drugs used for weight loss.

An appeal arguing medical need is unlikely to change that answer. More realistic steps:

Reading the denial letter

Job-based plans must name the specific plan provision behind a denial, and you can request a free copy of any criteria used. "Criteria not met" or "documentation not received" means an appeal with records can work. "Non-formulary" means an exception request. "Not covered for weight loss" means the plan reads the prescription as a weight-loss use; if you have diabetes, ask your doctor's office to correct the diagnosis on the request.

Also check your plan's drug list and the excluded services list in your Summary of Benefits and Coverage.

Formulary exceptions

In individual and small-group plans, 45 CFR 156.122(c) requires a decision within 72 hours, or 24 hours if you are mid-treatment or your health is at serious risk. A denial can go to an independent reviewer. Your doctor generally has to confirm that covered drugs have not worked, will not work as well, or are likely to cause harm.

If you are already taking Mounjaro and your plan drops it or you change plans, ask for the expedited version. Being in the middle of a course of treatment on a non-formulary drug counts as an urgent reason under the rule.

Job-based plans set their own exception rules; ask HR or check the plan document. Lilly's LillyDirect offers prescription and savings help.

What to send with the appeal

Put the appeal in writing and keep copies. Include:

  • A copy of the denial letter and your plan ID number.
  • The plan's written criteria for Mounjaro, which you can request for free.
  • A letter from your doctor stating the type 2 diabetes diagnosis, why Mounjaro was chosen, and, if relevant, your cardiovascular risk.
  • Recent lab results and visit notes.
  • A list of diabetes medicines you have tried, with dates, doses and what happened, including side effects.

If the plan says no again, ask whether your case can go to external review.

Medicare and Medicaid

Medicare.gov says Part D plans should cover GLP-1 drugs for type 2 diabetes. Part D plans must grant an exception when a non-formulary drug is medically necessary, and exceptions also reach step therapy and dose limits. Your prescriber's statement is required; the plan must decide within 72 hours, or 24 hours if expedited. Appeals are due within 65 days. See Part D appeals.

State Medicaid programs must cover GLP-1 drugs for diabetes. See Medicaid appeals.

Questions people ask

Why was Mounjaro denied when I have type 2 diabetes?

Check whether the plan did not get proof of the diagnosis, wants you to try another drug first, or prefers a different GLP-1. Ask for the criteria in writing and have your doctor send the chart notes and lab results that match them.

Will insurance cover Mounjaro for weight loss?

Mounjaro's approved uses are all for type 2 diabetes. Some insurers list weight loss as not covered, and Medicare Part D excludes drugs used for weight loss. Ask whether your plan covers Zepbound instead.

Does Medicare cover Mounjaro?

For type 2 diabetes, yes: Part D plans should cover GLP-1 drugs for that condition. Part D does not cover drugs used for weight loss.

What is a formulary exception?

A request asking your plan to cover a drug that is not on its drug list, or to waive a step therapy rule. Your doctor explains why the covered options will not work for you.

Sources

  1. U.S. Food and Drug Administration: Drugs@FDA: FDA-Approved Drugs (Mounjaro, NDA 215866)05/13/2022 ORIG-1 Approval Type 1 - New Molecular Entity
  2. U.S. Food and Drug Administration: NDA 215866/S-039 Supplement Approval letter for Mounjaro (December 19, 2025)including expansion of the currently approved indication to include pediatric patients aged 10 years and older with type 2 diabetes mellitus
  3. U.S. Food and Drug Administration: NDA 215866/S-044 and S-045 Supplement Approval letter for Mounjaro (August 27, 2026)including the addition of a new indication as a treatment to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events
  4. U.S. Food and Drug Administration: MOUNJARO (tirzepatide) injection prescribing information, August 2026 (Drugs@FDA)as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  5. U.S. Food and Drug Administration: FDA Approves New Medication for Chronic Weight ManagementTirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro
  6. KFF: 2026 Employer Health Benefits SurveyHealth plans generally have covered these medications when prescribed for people with diabetes
  7. Cigna Healthcare: Drug Coverage Policy IP0701: Diabetes – Glucagon-Like Peptide-1 Agonists for Employer Plans (effective 06/15/2026)Diagnosis of Type 2 diabetes mellitus [Documentation Required]
  8. Peterson-KFF Health System Tracker: Insurer strategies to control costs associated with weight loss drugsstep therapy is much less commonly used as a utilization management tool, with fewer than 1 in 4 Marketplace plans requiring step therapy for each of the drugs included in this analysis
  9. HealthCare.gov: Internal appealsYou must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied.
  10. HealthCare.gov: External ReviewAny denial that involves medical judgment where you or your provider may disagree with the health insurance plan
  11. Cigna Healthcare: Diabetes – Glucagon-Like Peptide-1 Agonists Prior Authorization Policy (Cigna National Formulary, review date 06/03/2026)Weight Loss Treatment. The products in this policy are not FDA-approved for weight loss.
  12. Legal Information Institute, Cornell Law School: 42 U.S. Code § 1395w-102 - Prescription drug benefitswhich may be excluded from coverage or otherwise restricted under section 1396r–8(d)(2) of this title
  13. Legal Information Institute, Cornell Law School: 42 U.S. Code § 1396r-8 - Payment for covered outpatient drugs(A) Agents when used for anorexia, weight loss, or weight gain.
  14. Centers for Medicare & Medicaid Services: Medicare GLP-1 BridgeThe Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.
  15. Medicare.gov: Weight loss drugsZepbound® (KwikPen® only. The program doesn’t cover single-dose Zepbound® vials or pens)
  16. eCFR (Office of the Federal Register): 29 CFR 2560.503-1 -- Claims procedureReference to the specific plan provisions on which the determination is based
  17. HealthCare.gov: Getting prescription medicationsVisit your insurer’s website to review a list of prescriptions your plan covers
  18. Centers for Medicare & Medicaid Services: Summary of Benefits and Coverage template (accessible format)Services Your Plan Generally Does NOT Cover (Check your policy or plan document for more information and a list of any other excluded services.)
  19. eCFR (Office of the Federal Register): 45 CFR 156.122 -- Prescription drug benefitsA health plan must make its determination on a standard exception and notify the enrollee or the enrollee's designee and the prescribing physician (or other prescriber, as appropriate) of its coverage determination no later than 72 hours following receipt of the request.
  20. Eli Lilly and Company: Online Pharmacy Service Options for Select Lilly Medicines | LillyDirect®LillyDirect is here to help you manage your prescriptions.
  21. eCFR (Office of the Federal Register): 42 CFR 423.578 -- Exceptions processThe Part D plan sponsor must grant an exception whenever it determines that the drug is medically necessary, consistent with the physician's or other prescriber's statement under paragraph (b)(5) of this section, and that the drug would be covered but for the fact that it is an off-formulary drug.
  22. eCFR (Office of the Federal Register): 42 CFR 423.568 -- Standard timeframe and notice requirements for coverage determinationsbut no later than 72 hours after receipt of the physician's or other prescriber's supporting statement
  23. eCFR (Office of the Federal Register): 42 CFR 423.572 -- Timeframes and notice requirements for expedited coverage determinationsbut no later than 24 hours after receipt of the physician's or other prescriber's supporting statement
  24. Medicare.gov: Appeals in a Medicare drug planmust ask for an appeal within 65 days from the date on the initial denial notice sent by your plan
  25. KFF: Medicaid Coverage of and Spending on GLP-1sMedicaid coverage of GLP-1 drugs for obesity treatment is optional for states, while coverage for other indications (diabetes, cardiovascular disease, and sleep apnea) is required.

This page is general information about appeal rules in the United States. It is not legal or medical advice. Rules can change, and your plan’s documents and your denial letter control the dates that apply to you.

Related guides